![An industrial worker operates equipment in a clean-room environment.](https://eu-images.contentstack.com/v3/assets/bltca5319cc2529b48a/blt0db0f490920d41e8/63dd147a80f43b130ca3502e/Pharmathen-_hero.jpg?format=webp&width=100)
Pharmathen
www.pharmathen.comRegion: | Europe |
---|---|
Sector: | Healthcare |
Investment Year: | 2015 |
Transaction Value: | €475m |
![Pharmathen logo](https://eu-images.contentstack.com/v3/assets/bltca5319cc2529b48a/blt88b9a499e7fa8d5f/63dd147a8a0fdf13012bb0ed/Pharmathen.png?format=webp&width=100)
In September 2015, BCEC IX acquired Pharmathen from the founding family. Pharmathen is a leading European pharmaceutical company focused upon developing, manufacturing and out-licensing complex generic drugs.
Pharmathen has a B2B Business Model and focuses on: out-licensing to over 265 customers in over 85 countries; Manufacturing Supply Agreements with minimum 5-year contracts; and a portfolio of 110 own-developed drugs. Additionally, Pharmathen undertakes R&D in Greece with 2 facilities, along with manufacturing at 2 facilities, also in Greece.
The company is headquartered in Amsterdam.
For more information on Pharmathen, please watch the video here.